XML 29 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended
Mar. 30, 2019
Mar. 31, 2018
Cash Flows From (For) Operating Activities    
Net income $ 63.9 $ 80.8
Adjustments to derive cash flows:    
Depreciation and amortization 96.6 109.5
Share-based compensation 12.4 12.7
Impairment charges 4.1 0.0
Change in financial assets (10.4) 9.6
Loss on extinguishment of debt 0.0 0.5
Restructuring charges 9.3 1.5
Deferred income taxes 3.9 (7.2)
Amortization of debt premium (1.9) (2.1)
Other non-cash adjustments, net 13.4 12.1
Subtotal 191.3 217.4
Increase (decrease) in cash due to:    
Accounts receivable (48.5) 2.6
Inventories (37.5) (43.7)
Accounts payable 75.4 57.5
Payroll and related taxes (19.9) (38.9)
Accrued customer programs (61.7) 17.3
Accrued liabilities (3.8) (24.0)
Accrued income taxes (10.0) 6.4
Other, net 9.2 (22.2)
Subtotal (96.8) (45.0)
Net cash from (for) operating activities 94.5 172.4
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 1.2 10.0
Royalty Pharma contingent milestone payment 250.0 0.0
Additions to property, plant and equipment (21.1) (13.4)
Net proceeds from sale of business and other assets 0.0 1.3
Net cash from (for) investing activities 230.1 (2.1)
Cash Flows From (For) Financing Activities    
Issuances of long-term debt 0.0 431.0
Payments on long-term debt (12.3) (444.5)
Borrowings (repayments) of revolving credit agreements and other financing, net (0.3) (6.2)
Deferred financing fees 0.0 (2.4)
Repurchase of ordinary shares 0.0 (108.1)
Cash dividends (25.9) (26.7)
Other financing, net (3.1) (5.7)
Net cash from (for) financing activities (41.6) (162.6)
Effect of exchange rate changes on cash and cash equivalents 3.8 0.9
Net increase (decrease) in cash and cash equivalents 286.8 8.6
Cash and cash equivalents, beginning of period 551.1 678.7
Cash and cash equivalents, end of period $ 837.9 $ 687.3